Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Change in Acquisitions & Divestments (2016 - 2025)

Cardiff Oncology's Change in Acquisitions & Divestments history spans 7 years, with the latest figure at $16.6 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 234.4% year-over-year to $16.6 million; the TTM value through Dec 2025 reached $71.1 million, up 592.75%, while the annual FY2025 figure was $71.1 million, 592.75% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $16.6 million at Cardiff Oncology, down from $53.3 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $76.4 million in Q4 2023 and bottomed at -$58.1 million in Q3 2023.
  • The 5-year median for Change in Acquisitions & Divestments is $15.2 million (2022), against an average of $14.4 million.
  • The largest annual shift saw Change in Acquisitions & Divestments skyrocketed 453.03% in 2022 before it plummeted 1423.97% in 2025.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $13.3 million in 2021, then rose by 14.49% to $15.2 million in 2022, then skyrocketed by 402.02% to $76.4 million in 2023, then plummeted by 116.14% to -$12.3 million in 2024, then skyrocketed by 234.4% to $16.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Change in Acquisitions & Divestments are $16.6 million (Q4 2025), $53.3 million (Q3 2025), and -$20.0 million (Q2 2025).